Table 2.

Consensus recommendations for RCI dose adjustment or discontinuation for management of selected adverse events (AEs) in patients receiving treatment with RCI for uveitis

Adverse event	Dose adjustment
	Down titrate if other interventions fail	Down titrate concomitantly with other interventions for severe AEs	Discontinue if other interventions fail	Discontinue for severe, significant AEs
Oedema	2.92 ± 1.61	3.62 ± 1.56	2.92 ± 1.85	4.23 ± 1.42
Anxiety/Depression	3.15 ± 1.46	3.62 ± 1.50	3.31 ± 1.70	4.15 ± 1.52
Infection	3.15 ± 1.82	3.62 ± 1.71	3.31 ± 1.97	4.00 ± 1.63
Increased Appetite/Weight Gain	2.85 ± 1.72	3.23 ± 1.92	3.15 ± 1.99	4.08 ± 1.61
Glucose Intolerance/Worsening in Glucose Control	3.31 ± 1.44	3.92 ± 1.44	3.54 ± 1.61	3.92 ± 1.75
Hypertension	2.85 ± 1.82	3.46 ± 1.94	3.00 ± 2.00	4.08 ± 1.50
Darkening of the Skin	2.54 ± 2.22	2.85 ± 2.34	2.62 ± 2.33	3.46 ± 2.07
Other Skin-related AEs	2.46 ± 2.18	3.15 ± 2.34	2.62 ± 2.43	3.54 ± 2.03
Localized Injection Site Pain	2.00 ± 2.83	2.38 ± 3.01	2.62 ± 2.14	3.38 ± 2.06
Insomnia	2.92 ± 1.71	3.15 ± 1.91	2.77 ± 1.88	3.77 ± 1.69

Recommendations that reached consensus are bold. Values are the mean ± standard deviation of the Likert scale scores (range: −5 to +5). Consensus was defined as a mean value ≥ 2.5 (for) or ≤−2.5 (against) with a standard deviation which did not cross zero.

AE = adverse event.